Example A — TURP for obstructive BPH
Clinical: Severe LUTS with urinary obstruction despite medication therapy.
Code(s): 52601 – Transurethral resection of prostate.
Dx: N40.1; add N13.8 when obstruction is documented.

Example B — UroLift® prostatic urethral lift (4 implants)
Clinical: Moderate LUTS treated with four transprostatic implants.
Code(s): 52441 – single (first) implant.
52442 x 3 – each additional implant (add-on code; no modifier 51).
Dx: N40.1.

Example C — Rezūm™ water vapor thermotherapy
Clinical: BPH treated using convective radiofrequency-generated water vapor therapy.
Code(s): 53854 – Transurethral destruction of prostate tissue by radiofrequency generated water vapor thermotherapy.
Dx: N40.1.

Example D — Aquablation® robotic waterjet ablation
Clinical: Obstructive BPH treated with ultrasound-guided robotic waterjet ablation.
Code(s): 52597 – Transurethral waterjet ablation of prostate (DOS on/after 1/1/2026; 0421T for earlier dates of service).
Dx: N40.1; add N13.8 when obstruction is documented.

• Symptom severity: LUTS severity and IPSS score when available
• Medication history: prior medication therapy and response/intolerance
• Diagnostics: testing results supporting obstruction (uroflow, PVR, cystoscopy, ultrasound)
• Procedure detail: technology used and operative findings describing obstruction
• Implant count: number of implants placed (UroLift®) — drives 52442 units

• Problem status: state whether BPH (and any co-managed conditions) is stable or worsening
• Data reviewed: reference PSA, UA, PVR, or uroflow results actually used in decision-making
• Prescription drug management: document the drug, dose, response, risk/benefit discussion, and the shared decision to continue — "refill given" alone does not qualify

• Missing medical necessity: document failed medication therapy and severity of symptoms.
• Incorrect bundling: verify cystoscopy inclusion in procedure descriptors before reporting it separately.
• Technology mismatch: ensure the CPT® code reflects the specific treatment performed (e.g., do not report deleted 0421T for 2026 Aquablation® cases).
• Diagnostic support missing: include testing demonstrating obstruction.
• E/M downcoding: level 4 follow-ups without documented prescription drug management are being automatically downcoded — appeal only when the note truly supports the level.

• 52601 – Transurethral electrosurgical resection of prostate (TURP), complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included)
• 52450 – Transurethral incision of prostate (TUIP)
• 52648 – Laser vaporization of prostate
• 52649 – Laser enucleation of prostate (HoLEP) — do not confuse with waterjet ablation

• 52441 – Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant (UroLift® — first implant)
• 52442 – each additional permanent adjustable transprostatic implant (UroLift®; add-on code — list separately in addition to 52441; do not append modifier 51)
• 53854 – Transurethral destruction of prostate tissue by radiofrequency generated water vapor thermotherapy (Rezūm™)
• 52597 – Transurethral waterjet ablation of prostate (Aquablation®) — Category I code effective January 1, 2026; replaces deleted Category III code 0421T. Use 0421T only for dates of service before 1/1/2026.

• 37243 – Vascular embolization or occlusion; for tumors, organ ischemia, or infarction — the primary code for PAE
• 37242 – Vascular embolization or occlusion; arterial, other than hemorrhage or tumor — report in addition only when a separate, clearly documented arterial territory outside the standard prostatic supply was treated [VERIFY: RAC audit guidance]

• 52000 – Cystourethroscopy (diagnostic)
• 51741 – Complex uroflowmetry
• 51798 – Post-void residual, ultrasound, non-imaging
• 76872 – Ultrasound, transrectal

• N40.0 – Benign prostatic hyperplasia without lower urinary tract symptoms
• N40.1 – Benign prostatic hyperplasia with lower urinary tract symptoms
• N40.2 – Nodular prostate without lower urinary tract symptoms
• N40.3 – Nodular prostate with lower urinary tract symptoms
• N13.8 – Other obstructive and reflux uropathy — report when bladder outlet obstruction is documented

Tip: With N40.1, ICD-10 instructs "use additional code" for documented associated symptoms — e.g., R35.0 urinary frequency, R35.1 nocturia, R39.11 hesitancy, R39.12 weak stream, R33.8 other retention, N13.8 obstruction. Coding the documented symptoms strengthens medical necessity for diagnostics and intervention.

• Symptom severity: severity of symptoms and urinary obstruction, IPSS when available
• Diagnostic evidence: testing supporting the treatment decision
• Anatomy: prostate size or anatomical findings
• Failed medical therapy: documented when surgery is performed
• Procedure detail: technology used and number of implants placed
• E/M follow-ups: for level 4 visits, document the problems managed, data reviewed, and a true prescription-drug-management discussion — not just "refill given"

• -25 when a significant, separately identifiable E/M service occurs on the same day as a procedure. Watch item: the CY2027 PFS proposed rule would apply the multiple-procedure payment reduction to E/M services reported with modifier -25 (the lower-valued service on the day would be cut 50%) [VERIFY: proposed rule — not final]
• 51-exempt add-on: never append modifier 51 to 52442

• The surgical BPH procedures carry a 90-day global period: 52601, 52450, 52648, 52649, 53854, 52597.
• Exception: UroLift® 52441 carries a 0-day global (add-on 52442 is ZZZ) per the July 2026 Medicare RVU file [VERIFY: corrected per PPRRVU2026_Jul_QPP — confirm].
• Confirm using your MAC/payer fee schedule.

• Verify payer policies for minimally invasive technologies — several MACs maintain LCDs/billing articles for waterjet ablation and water vapor thermotherapy [VERIFY: current MAC policies].
• Some treatments require prior authorization.
• PAE RAC audits: Recovery Audit Contractors are reviewing claims where 37242 and 37243 were reported together. Documentation must clearly support any additional arterial territory treated beyond the standard bilateral prostatic supply; expect pre-payment records requests for the arteriograms and selective catheterizations [VERIFY: RAC activity, Q2 2026].

• Same CPT® codes apply in the facility setting: 52441/52442 (UroLift®), 53854 (Rezūm™), 52601 (TURP), 52597 (Aquablation®), 37243 (PAE).
• Facility charge capture: capture device or implant charges when UroLift® is performed — device-intensive packaging may apply [VERIFY: device-intensive status].
• Aquablation®: confirm the OPPS/ASC status indicator and APC assignment for 52597; 0421T applies only to dates of service before 1/1/2026 [VERIFY: current SI/APC].
• Supplies: capture per facility policy and packaging rules; verify facility coding policies for newer technologies such as waterjet ablation.

• N40.0 – Benign prostatic hyperplasia without LUTS
• N40.1 – Benign prostatic hyperplasia with LUTS
• N13.8 – Other obstructive and reflux uropathy — report when bladder outlet obstruction is documented

Facility tip: the facility claim's diagnosis coding should align with the physician operative note — mismatched dx sequencing between the professional and facility claims is an avoidable denial driver.

• Procedure performed: including the specific technology used
• Implant/device documentation: when applicable, including the number of UroLift® implants
• Medical necessity: diagnostic support in the facility record
• Record alignment: op note, nursing record, supply log, and charge capture must tell the same story

• Packaging rules vary: between ASC and hospital outpatient settings.
• Device-intensive procedures: may require detailed supply documentation.
• Site-of-service variance: office vs ASC vs HOPD payment differentials are significant for BPH technologies — model the economics before shifting site of service.
• Payer guidance: confirm payer coverage rules and facility compliance policy.